Antengene Reports Promising Clinical Findings on Selinexor at ASH 2024
Antengene Reports Promising Clinical Findings on Selinexor at ASH 2024
Antengene Corporation Limited, a prominent global biopharmaceutical firm focused on developing cutting-edge treatments for hematologic malignancies and solid tumors, recently presented pivotal data regarding Selinexor at the 2024 American Society of Hematology Annual Meeting (ASH 2024). This event highlighted findings from two late-stage clinical studies that underscore the drug's effectiveness in challenging cancer types.
Insights from the BENCH Study
One of the major studies discussed was the BENCH study, a Phase III clinical trial investigating the effectiveness of a treatment regimen combining Selinexor with Bortezomib and Dexamethasone (referred to as SVd) compared to the standard treatment of Bortezomib and Dexamethasone (Vd) in adult patients with Relapsed and Refractory Multiple Myeloma (R/R MM). Conducted across various centers in China, this open-label trial enrolled 154 participants, specifically selected for their previous treatment histories.
The results were compelling: the median progression-free survival (mPFS) for the SVd group reached 8.1 months, in stark contrast to 6.3 months for the Vd group. Moreover, the study revealed that the overall response rate (ORR) was significantly higher in patients treated with SVd, with a notable increase in those achieving a very good partial response (VGPR) or better. The timeline for clinical responses also illustrated the SVd regimen's effectiveness, showcasing a median time to response of just 0.8 months against 1.4 months for the Vd group.
Safety profiles were also evaluated, and while treatment-emergent adverse events (TEAEs) were reported, notably higher grades of thrombocytopenia and lymphocytopenia were observed, particularly in SVd participants. Importantly, there was a marked decrease in incidences of peripheral neuropathy in the SVd group compared to Vd, demonstrating a more favorable safety profile for Selinexor in this cohort.
Preliminary Findings from the TOUCH Study
The second study presented, labeled the TOUCH study, focused on the application of Selinexor in combination with the anti-PD-1 antibody Tislelizumab for patients facing Relapsed or Refractory Extranodal NK/T-cell Lymphoma (R/R ENKTL). This multicenter trial, still in its early stages, emphasizes safety and tolerability in a defined subset of patients, all of whom had previously received treatment involving checkpoint inhibitors, some of whom had relapsed post-Tislelizumab therapy.
Among the enrolled 17 patients, the efficacy outcomes were encouraging. An overall response rate of 75% was noted, with a median progression-free survival of 6.7 months. TEAEs were recorded in all participants, yet the majority appeared manageable, paving the way for further exploration into Selinexor's role in overcoming drug resistance in ENKTL.
The data presented at ASH 2024 aligns with Antengene's commitment to advancing novel therapeutic options for diverse cancer types, reinforcing their vision of 'Treating Patients Beyond Borders.' With ongoing innovations and data generation, Antengene's expanding portfolio is set to reshape treatment paradigms in oncology.
In conclusion, the findings from these late-stage trials reveal not just the potential of Selinexor as an effective treatment for specific hematologic malignancies but also reflect Antengene's dedication to pushing the boundaries of cancer care through rigorous research and development initiatives. Further investigations and real-world applications will be crucial in the journey towards more effective cancer treatments that enhance patient outcomes across the globe.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.